MARKET

SBPH

SBPH

Spring Bk Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8799
-0.0172
-1.92%
Closed 16:00 04/03 EDT
OPEN
0.8971
PREV CLOSE
0.8971
HIGH
0.8971
LOW
0.8200
VOLUME
78.60K
TURNOVER
--
52 WEEK HIGH
11.00
52 WEEK LOW
0.8000
MARKET CAP
13.37M
P/E (TTM)
-0.6009
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SBPH stock price target is 1.733 with a high estimate of 2.000 and a low estimate of 1.500.

EPS

SBPH News

More
  • More COVID-19 actions - healthcare
  • seekingalpha · 1d ago
  • Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic
  • GlobeNewswire · 2d ago
  • Spring Bank Pharma Highlights Update On Business Operations, Clinical Program Progress
  • Benzinga · 2d ago
  • Should You Take Comfort From Insider Transactions At Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH)?
  • Simply Wall St. · 5d ago

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About SBPH

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus (HBV). The Company's inarigivir selectively activates within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1 (RIG-I), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company also developing a second STING (STimulator of INterferon Genes) agonist product candidate, SB 11285, which is an immunotherapeutic agent for the potential treatment of selected cancers. The Company lead product is inarigivir.
More

Webull offers kinds of Spring Bank Pharmaceuticals Inc stock information, including NASDAQ:SBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SBPH stock news, and many more online research tools to help you make informed decisions.